Search results for "prova"
showing 10 items of 152 documents
Il contributo peritale e il ruolo dell’esperto
2019
Il contributo esplora le problematiche poste dalla metabolizzazione della prova scientifica nell’accertamento penale della responsabilità per colpa medica, alla luce del quadro complessivo ridisegnato dalla l. n. 24 del 2017 (c.d. legge “Gelli-Bianco”): ripercorsi gli sviluppi giurisprudenziali in tema di metodologie di elaborazione della prova scientifica, ci si sofferma sul ruolo delle linee guida e delle buone pratiche clinico-assistenziali e sul controllo, in sede giudiziaria, del giudizio di adeguatezza esercitato dal sanitario nel caso clinico sottoposto al suo esame; sono, quindi, approfondite le metodiche attraverso le quali il giudice penale si interfaccia al sapere dell’esperto e,…
Quantum Security Proofs Using Semi-classical Oracles
2019
We present an improved version of the one-way to hiding (O2H) Theorem by Unruh, J ACM 2015. Our new O2H Theorem gives higher flexibility (arbitrary joint distributions of oracles and inputs, multiple reprogrammed points) as well as tighter bounds (removing square-root factors, taking parallelism into account). The improved O2H Theorem makes use of a new variant of quantum oracles, semi-classical oracles, where queries are partially measured. The new O2H Theorem allows us to get better security bounds in several public-key encryption schemes.
Nintedanib in non-small cell lung cancer: from preclinical to approval
2015
Angiogenesis is a driving force of a tumor’s development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and many others. The latest drug of this class to be approved for patients with non-small cell lung cancer (NSCLC) was nintedanib, a triple angiokinase inhibitor. This molecule targets vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and fibroblast growth factor (FGF) pathways, avoiding the tumor’s switch to normal escape mechanisms. The pharmacokine…
The European directive on traditional herbal medicinal products: friend or foe for plant-based therapies?
2012
Biowaiver monographs for immediate release solid oral dosage forms: quinidine sulfate.
2009
Literature data are reviewed relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing quinidine sulfate. Quinidine sulfate's solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. The available data are not fully conclusive, but do suggest that quinidine sulfate is highly soluble and moderately to highly permeable and would likely be assigned to BCS Class I (or at worst BCS III). In view of the inconclusiveness of the data and, more imp…
LA RINEGOZIAZIONE DEGLI ACCORDI DI RISTRUTTURAZIONE DEI DEBITI
2021
L’articolo ha per oggetto l’esame critico, con un tentativo di sviluppo anche rispetto ad ipotesi non espressamente regolate, dell’art. 58 del nuovo Codice della crisi di impresa e di insolvenza, che disciplina oggi la materia della rinegoziazione degli accordi di ristrutturazione e delle modifiche del piano, distinguendo fra la fase precedente e quella successiva all’omologazione The essay focuses – with a critical approach, also aimed to develope further implementation events – on the Section 58 of the new Crisis and Insolvency Code, now regulating the Renegotiation of Debt Restructuring Agreements, in order to face their shortcomings as well as adjustment needs, by introducing different …
The evolution of European Medicines Agency drug approval: the adaptive licensing
2016
Editorial without abstract
I diritti nel processo tra eccezioni in senso stretto e mere difese: osservazioni in margine a sez.un.2951/2016
2017
Il saggio illustra come, a seconda del tipo di diritto dedotto in giudizio, muti la distribuzione dell'onere probatorio tra attore e convenuto